SCHEMBL2949519

SCHEMBL2949519

CCCNc1ccc2ncc(-c3ccc(O)cc3)n2n1

nearest known ligand 0.77

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FYN P06241 14/20 0.77
PIM1 P11309 3/20 0.64
CCNT1 O60563 1/20 0.64
ABL1 P00519 1/20 0.64
PGK1 P00558 1/20 0.64
CDK1 P06493 1/20 0.64
CCNB1 P14635 1/20 0.64
CCNA2 P20248 1/20 0.64
CDK2 P24941 1/20 0.64
CSNK1E P49674 1/20 0.64
GSK3A P49840 1/20 0.64
GSK3B P49841 1/20 0.64
CDK9 P50750 1/20 0.64
JAK3 P52333 1/20 0.64
CDK5 Q00535 1/20 0.64
CDK5R1 Q15078 1/20 0.64
HASPIN Q8TF76 1/20 0.64
AURKB Q96GD4 1/20 0.64
MKNK1 Q9BUB5 4/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4694858 0.88 FYN (0.75) FYNPIM1CCNT1ABL1PGK1
SCHEMBL2941494 0.88 MKNK1 (0.79) FYNPIM1MKNK1
SCHEMBL2947115 0.87 FYN (0.73) FYNPIM1CCNT1ABL1PGK1
SCHEMBL3037215 0.87 FYN (1.00) FYNPIM1CCNT1ABL1PGK1
SCHEMBL19467085 0.86 FYN (0.72) FYNPIM1CCNT1ABL1PGK1
SCHEMBL13234625 0.86 FYN (1.00) FYNPIM1CCNT1ABL1PGK1
SCHEMBL2950581 0.86 FYN (0.72) FYNPIM1CCNT1ABL1PGK1
SCHEMBL2949802 0.86 FYN (0.80) FYNPIM1MKNK1
SCHEMBL1055002 0.86 MKNK1 (0.80) FYNPIM1MKNK1
SCHEMBL30521854 0.85 FYN (1.00) FYNPIM1CCNT1ABL1PGK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1900739-A1 Diazolodiazine derivatives as kinase inhibitors CELLZOME AG (DE) 2008-03-19 EP claimed
WO-2008025822-A1 DIAZOLODIAZINE DERIVATIVES AS KINASE INHIBITORS CELLZOME LIMITED (GB) 2008-03-06 WO claimed
US-7750000-B2 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER SCHERING PHARMA AG (DE) 2010-07-06 US disclosed
US-7750000-B2 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER SCHERING PHARMA AG (DE) 2010-07-06 US disclosed
EP-1900739-A1 Diazolodiazine derivatives as kinase inhibitors CELLZOME AG (DE) 2008-03-19 EP disclosed
WO-2008025822-A1 DIAZOLODIAZINE DERIVATIVES AS KINASE INHIBITORS CELLZOME LIMITED (GB) 2008-03-06 WO disclosed
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER INTELLECTUAL PROPERTY GMBH (DE) 2007-04-26 US disclosed
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER INTELLECTUAL PROPERTY GMBH (DE) 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments MAP4K2, MAP3K1, MAP3K2 FYN 421/4885PIM1 365/4885CCNT1 773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.